Department of Musculoskeletal Tumor, Peking University People's Hospital, Beijing, China.
Beijing Key Laboratory of Musculoskeletal Tumor, Peking University People's Hospital, Beijing, China.
Front Immunol. 2023 Sep 1;14:1257254. doi: 10.3389/fimmu.2023.1257254. eCollection 2023.
Chordoma is a rare malignant bone tumor with limited therapeutic options, which is resistant to conventional chemotherapy and radiotherapy, and targeted therapy is also shown with little efficacy. The long-standing delay in researching its mechanisms of occurrence and development has resulted in the dilemma of no effective treatment targets and no available drugs in clinical practice. In recent years, the role of the tumor immune microenvironment in driving tumor growth has become a hot and challenging topic in the field of cancer research. Immunotherapy has shown promising results in the treatment of various tumors. However, the study of the immune microenvironment of chordoma is still in its infancy. In this review, we aim to present a comprehensive reveal of previous exploration on the chordoma immune microenvironment and propose promising immunotherapy strategies for chordoma based on these characteristics.
脊索瘤是一种罕见的恶性骨肿瘤,治疗选择有限,对常规化疗和放疗具有抗药性,而靶向治疗的效果也不佳。长期以来,对其发生和发展机制的研究滞后,导致临床上缺乏有效的治疗靶点和可用药物。近年来,肿瘤免疫微环境在驱动肿瘤生长中的作用成为癌症研究领域的一个热点和极具挑战性的课题。免疫疗法在治疗各种肿瘤方面已显示出良好的效果。然而,脊索瘤免疫微环境的研究仍处于起步阶段。在这篇综述中,我们旨在全面揭示脊索瘤免疫微环境的前期探索,并根据这些特征提出有前途的脊索瘤免疫治疗策略。